MedTrace Logo

A Follow up Study of Group B Streptococcus (GBS)-NN/NN2 Vaccine in Healthy Volunteers

NCT06280157 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 29

Last updated 2026-02-25

No results posted yet for this study

Summary

The goal of this follow-up study is to investigate the persistence of the immune response induced by the GBS-NN/NN2 vaccine in women who have participated in study MVX0002, and/or in study MVX0003 with GBS-NN/NN2 vaccine and received 1, 2 or 3 doses of GBS-NN/NN2. The main question it aims to answer is to determine the persistence of the immune response induced by the GBS-NN/NN2 vaccine by measuring antibody concentrations.

Participants who had received a primary course of GBS-NN/NN2 in Study MVX0002 and/or MVX0003 will be invited to return to have a single yearly blood sample of approximately 10 mL collected 2 to 5 years after the completion of the previous vaccination.

Conditions

  • Group B Streptococcus Infection

Interventions

BIOLOGICAL

GBS-NN/NN2

GBS-NN/NN2 containing 50 μg of GBS-NN and 50 μg of GBS/NN2

Sponsors & Collaborators

  • Simbec-Orion Group

    collaborator INDUSTRY

  • Minervax ApS

    lead OTHER

Principal Investigators

  • Ebbe Englev · Study Director

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-18
Primary Completion
2025-12-01
Completion
2025-12-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06280157 on ClinicalTrials.gov